JPS6358808B2 - - Google Patents
Info
- Publication number
- JPS6358808B2 JPS6358808B2 JP53075944A JP7594478A JPS6358808B2 JP S6358808 B2 JPS6358808 B2 JP S6358808B2 JP 53075944 A JP53075944 A JP 53075944A JP 7594478 A JP7594478 A JP 7594478A JP S6358808 B2 JPS6358808 B2 JP S6358808B2
- Authority
- JP
- Japan
- Prior art keywords
- sickle cell
- hemoglobin
- sickle
- red blood
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 150000003222 pyridines Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 22
- 208000007056 sickle cell anemia Diseases 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229960002726 vincamine Drugs 0.000 description 5
- 206010024264 Lethargy Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- ACGQXXFERIKZRY-UHFFFAOYSA-N 2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-1-phenylethanol;hydrochloride Chemical class Cl.C1CC=2SC=CC=2CN1CC(O)C1=CC=CC=C1 ACGQXXFERIKZRY-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000011720 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 1
- 229960004318 dihydroergocristine Drugs 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7719161A FR2395028A2 (fr) | 1977-06-22 | 1977-06-22 | Derives pyridiniques, leur preparation et leurs application therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5441332A JPS5441332A (en) | 1979-04-02 |
| JPS6358808B2 true JPS6358808B2 (xx) | 1988-11-17 |
Family
ID=9192421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7594478A Granted JPS5441332A (en) | 1977-06-22 | 1978-06-22 | Treating composition of sickle shaped erythrocyte disease |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US4210649A (xx) |
| JP (1) | JPS5441332A (xx) |
| FR (1) | FR2395028A2 (xx) |
| IT (1) | IT1105366B (xx) |
| OA (1) | OA05991A (xx) |
| PH (1) | PH14251A (xx) |
| ZA (1) | ZA783512B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824400D0 (en) * | 1988-10-18 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| JP2673721B2 (ja) * | 1989-05-24 | 1997-11-05 | キヤノン株式会社 | 定着装置 |
| DE69228782T2 (de) * | 1991-08-01 | 1999-10-21 | Canon K.K., Tokio/Tokyo | Elastischer Gegenstand, elastische Walze und Fixiervorrichtung |
| CA2200469A1 (en) * | 1994-10-11 | 1996-04-18 | Takeda Chemical Industries, Ltd. | Condensed compounds, their production and use |
| DE60028538T2 (de) | 1999-01-19 | 2007-06-21 | Neurosearch A/S | Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215948B1 (xx) * | 1973-02-01 | 1976-05-14 | Centre Etd Ind Pharma |
-
1977
- 1977-06-22 FR FR7719161A patent/FR2395028A2/fr active Granted
-
1978
- 1978-06-20 IT IT49942/78A patent/IT1105366B/it active
- 1978-06-20 US US05/917,374 patent/US4210649A/en not_active Expired - Lifetime
- 1978-06-20 ZA ZA00783512A patent/ZA783512B/xx unknown
- 1978-06-22 JP JP7594478A patent/JPS5441332A/ja active Granted
- 1978-06-22 PH PH21292A patent/PH14251A/en unknown
- 1978-06-22 OA OA56537A patent/OA05991A/xx unknown
-
1980
- 1980-05-19 US US06/150,890 patent/US4335128A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5441332A (en) | 1979-04-02 |
| FR2395028A2 (fr) | 1979-01-19 |
| IT7849942A0 (it) | 1978-06-20 |
| IT1105366B (it) | 1985-10-28 |
| FR2395028B2 (xx) | 1980-04-25 |
| US4210649A (en) | 1980-07-01 |
| US4335128A (en) | 1982-06-15 |
| ZA783512B (en) | 1979-06-27 |
| OA05991A (fr) | 1981-06-30 |
| PH14251A (en) | 1981-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morgan et al. | Beta‐adrenergic receptor blocking drugs, hypertension and plasma renin. | |
| Dworkin et al. | Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR | |
| LUETSCHER JR et al. | Severe injury to kidneys and brain following sulfathiazole administration: high serum sodium and chloride levels and persistent cerebral damage | |
| Pickard et al. | Controlled trial of cimetidine in acute upper gastrointestinal bleeding. | |
| Mackay et al. | Minoxidil in the management of intractable hypertension | |
| WAKEFIELD et al. | Schistosomiasis of the spinal cord | |
| JPS6358808B2 (xx) | ||
| Sigurdsson et al. | Formic acid burn—Local and systemic effects Report of a case | |
| WAIFE et al. | Fatal mercurial poisoning following prolonged administration of mercurophylline | |
| Hoffman et al. | MANAGEMENT OF LOWER NEPHRON NEPHROSIS: Report of Six Cases | |
| Horne | Tuberculous meningitis: problems in pathogenesis and treatment | |
| Harmon | Human mercuric chloride poisoning by intravenous injection | |
| Mair et al. | Medical treatment of equine colic | |
| Moore et al. | Bromide Intoxication. pp 1–13 | |
| GM et al. | Discussion on the treatment of anuria. | |
| Wein et al. | Oral methylene blue and the dissolution of renal calculi | |
| Munro et al. | Acute ethylene glycol poisoning: report of a fatal case | |
| CN113425723B (zh) | Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用 | |
| Bulmer | Experimental research on distribution and elimination of organic arsenic compounds after intravenous administration | |
| Lillie | Tryparsamide Treatment of Syphilis of the Central Nervous System: Observations from an Ophthalmologic Standpoint | |
| Clifford et al. | Dimethyl myleran therapy combined with abdominal aortic occlusion | |
| Bruce | The Ocular Fundus in Pheochromocytoma of the Adrenal Gland. Report of 3 Cases | |
| VAN WEZEL | Purpura and Neutropenia in Trimethadione Therapy: Report of a Case with Recovery | |
| Friedlander | Cortisone as an adjunct in the therapy of acute gout | |
| Kapustianskyi | Rationality of non-steroidal anti-inflamatory drugs usage in acute pain syndrome treatment |